TP53 and cancer: Given the essential roles played by p53 in maintaining the therapeutic‐responsive CAF hierarchy and thus cancer cell drug sensitivity, it is plausible to assume that the demonstrated efficacy of CAP in restoring the therapeutic response of many resistant cancer cells is, at least partially, attributable to the remodeled p53‐driven CAF hierarchy in the TME (Figure 3).